Opin vísindi

Fletta eftir höfundi "Österlund, Jenny"

Fletta eftir höfundi "Österlund, Jenny"

Röðun: Raða: Niðurstöður:

  • Icon
    Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration 
    Michelsen, Brigitte; Lindström, Ulf; Codreanu, Catalin; Ciurea, Adrian; Zavada, Jakub; Loft, Anne Gitte; Pombo-Suarez, Manuel; Onen, Fatos; Kvien, Tore K; Rotar, Ziga; Santos, Maria Jose; Iannone, Florenzo; Hokkanen, Anna-Mari; Gudbjornsson, Bjorn; Askling, Johan; Ionescu, Ruxandra; Nissen, Michael J; Pavelka, Karel; Sanchez-Piedra, Carlos; Akar, Servet; Sexton, Joseph; Tomsic, Matija; Santos, Helena; Sebastiani, Marco; Österlund, Jenny; Geirsson, Arni Jon; Macfarlane, Gary; van der Horst-Bruinsma, Irene; Georgiadis, Stylianos; Brahe, Cecilie Heegaard; Ørnbjerg, Lykke Midtbøll; Hetland, Merete Lund; Østergaard, Mikkel (BMJ, 2020-09-01)
    OBJECTIVES: To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) ...
  • Icon
    Is the risk of infection higher during treatment with secukinumab than with TNF-inhibitors? : An observational study from the Nordic countries 
    Glintborg, Bente; Di Giuseppe, Daniela; Wallman, Johan K; Provan, Sella A; Nordström, Dan; Hokkanen, Anna-Mari; Österlund, Jenny; Kristianslund, Eirik; Kvien, Tore K; Guðbjörnsson, Björn; Hetland, Merete Lund; Michelsen, Brigitte; Jacobsson, Lennart; Askling, Johan; Lindström, Ulf (2022-06-20)
    OBJECTIVES: The positioning of secukinumab in the treatment of axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) is debated, partly due to a limited understanding of the comparative safety of available treatments. We aimed to assess risk ...